GoodRx (GDRX) vs Phreesia (PHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
GoodRx (GDRX) has outperformed Phreesia (PHR) over the past year, losing 26.1% versus a loss of 54.7%. Over five years, PHR leads with a -83.0% price change compared with -91.9% for GDRX. GoodRx is the larger company by market cap ($1.17 billion vs $671.0 million), about 1.7 times the size.
On valuation, Phreesia trades at a lower forward P/E (6.7x vs 9.7x for GoodRx).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GDRX | PHR |
|---|---|---|
| Share price | $3.43 | $10.81 |
| Market cap | $1.17B | $670.99M |
| 1-day change | +2.08% | +1.41% |
| YTD return | +26.57% | -36.11% |
| 1-year return | -26.08% | -54.66% |
| 5-year return | -91.91% | -83.02% |
| P/E ratio (TTM) | 68.60 | 63.59 |
| Forward P/E | 9.67 | 6.70 |
| EPS (TTM) | $0.05 | $0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $796.85M | — |
| Revenue growth (YoY) | +0.57% | — |
| Net income (latest FY) | $30.44M | — |
| Gross margin | 92.77% | — |
| Operating margin | 10.98% | — |
| Net margin | 3.82% | — |
| 52-week high | $4.33 | $24.13 |
| 52-week low | $1.77 | $7.77 |
| Distance from 52-week high | -20.79% | -55.20% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +15.16% | +30.16% |
| Average volume | 1.28M | 741.54K |
| Shares outstanding | 107.18M | 62.07M |
| Employees | 697 | 1,789 |
| Sector | Healthcare | Consumer Discretionary |
| Industry | Health Information Services | Business Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GDRX has outperformed PHR by 28.6 percentage points over the past year.
- The two companies sit in different sectors: GoodRx in Healthcare and Phreesia in Consumer Discretionary.
About GoodRx
GDRX stock →GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Healthcare · Health Information Services · 697 employees
About Phreesia
PHR stock →Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada.
Consumer Discretionary · Business Services · 1,789 employees
GDRX vs PHR FAQ
Which is bigger, GoodRx or Phreesia?
GoodRx (GDRX) is larger, with a market capitalization of $1.17B compared with $670.99M for Phreesia (PHR).
Which stock has performed better over the past year, GDRX or PHR?
GDRX returned -26.08% over the past 12 months, compared with -54.66% for PHR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GDRX or PHR?
PHR has the lower trailing P/E at 63.6, versus 68.6 for GDRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are GoodRx and Phreesia in the same industry?
No. GoodRx is in the Healthcare sector, while Phreesia is in Consumer Discretionary.